Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.1K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.1K
Tumor Progression02:07

Tumor Progression

3.1K
3.1K
Cancer Survival Analysis01:21

Cancer Survival Analysis

855
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
855

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chondrosarcoma: the impact of comorbidity - 30 years of experience from a population-based database including 199 consecutive chondrosarcoma patients.

Orthopedic research and reviews·2019
Same author

Relative mortality in soft tissue sarcoma patients: a Danish population-based cohort study.

BMC cancer·2014
Same author

Alarm symptoms of soft-tissue and bone sarcoma in patients referred to a specialist center.

Acta orthopaedica·2014
Same author

The importance of standardized treatment in high-grade osteosarcoma: 30 years of experience from a hospital-based database.

Acta oncologica (Stockholm, Sweden)·2014
Same author

Comorbidity in adult bone sarcoma patients: a population-based cohort study.

Sarcoma·2014
Same author

Prognostic factors for local recurrence and mortality in adult soft tissue sarcoma of the extremities and trunk wall: a cohort study of 922 consecutive patients.

Acta orthopaedica·2014

Related Experiment Video

Updated: Apr 21, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

8.5K

Prognostic factors in soft tissue sarcoma.

Katja Maretty-Nielsen1

  • 1Department of Experimental Clinical Oncology, Aarhus University Hospital, Noerrebrogade 44, 8000 Aarhus C, Denmark. k.maretty@dadlnet.dk.

Danish Medical Journal
|November 6, 2014
PubMed
Summary

This study validates the Aarhus Sarcoma Registry (ASR) for soft tissue sarcoma (STS) research. It identifies key prognostic factors like comorbidity and biomarkers, crucial for improving survival rates in STS patients.

Area of Science:

  • Oncology
  • Epidemiology
  • Biostatistics

Background:

  • Soft tissue sarcoma (STS) survival has not improved despite advances.
  • Accurate prognostic data is vital for identifying patients for aggressive treatment.
  • Previous STS prognostic studies suffered from bias and methodological limitations.

Purpose of the Study:

  • To investigate the prognosis of STS patients using validated data from the Aarhus Sarcoma Registry (ASR).
  • To identify key prognostic factors including patient, tumor, treatment, comorbidity, and biomarker-related variables.
  • To improve statistical methods for more reliable STS prognostic studies.

Main Methods:

  • Systematic validation of the Aarhus Sarcoma Registry (ASR) data.
  • Competing risk analysis and Cox proportional hazard regression for prognostic factor identification.

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

13.7K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

1000

Related Experiment Videos

Last Updated: Apr 21, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

8.5K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

13.7K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

1000
  • Inclusion of continuous variables as cubic splines and adjustment for confounders using directed acyclic graphs.
  • Analysis of comorbidity using national registries and assessment of biomarker impact on mortality.

    • Main Results:

    • The ASR was validated as a reliable data source, including 85.3% of STS patients in western Denmark (1979-2008).
    • Key prognostic factors for disease-specific mortality included age, symptom duration, tumor size, location, and radiotherapy.
    • Comorbidity and pretreatment biomarkers (albumin, hemoglobin, neutrophil-to-lymphocyte ratio) were independent prognostic factors.

    Conclusions:

    • The Aarhus Sarcoma Registry is a valid population-based data source for STS research.
    • Improved statistical methodologies are essential for unbiased STS prognostic studies.
    • Comorbidity and biomarkers are critical for identifying high-risk STS patients who may benefit from intensified treatment.